Phcog.Net logo
Submit

BROWSE ALL JOURNALS

    SEE ALL 6 JOURNALS
    Journal of Pharmacology and PharmacotherapeuticsNOW IN
    Article

    Efficacy and Tolerability of Olmesartan, Telmisartan, and Losartan in Patients of Stage I Hypertension: A Randomized, Open‑label Study

    Mrunalini Kalikar1★, Kundan S. Nivangune1, Ganesh N. Dakhale1, Chaitali S. Bajait1, Smita D. Sontakke1, Vijay M. Motghare1, Ritu Budania1★ Corresponding author

    1. 1Department of Pharmacology, Government Medical College, Nagpur, Maharashtra, India.

    CORRESPONDENCE

    Mrunalini Kalikar

    Department of Pharmacology, Government Medical College, Nagpur, Maharashtra, India.

    mrunalinikalikar@yahoo.com

    Received: 11-03-2017; Revised: 11-06-2017; Accepted: 10-07-2017.

    Volume 8, Issue 3 · pp. 106–111 · PUBLISHED 2017 · DOI: 10.4103/jpp.JPP_39_17

    View on J Pharmacol. Pharmacother. original site ↗

    ABSTRACT

    Objectives: To compare the efficacy and tolerability of losartan, telmisartan, and olmesartan as antihypertensive agents and evaluate and compare their effects on lipid profile and blood glucose. Materials and Methods: This was a randomized, open‑label, parallel‑group, comparative study conducted in sixty patients of Stage I hypertension. The eligible patients were randomly allocated into three treatment groups: (1) Tablet olmesartan (20 mg), (2) Tablet telmisartan (40 mg), and (3) Tablet losartan (50 mg). Blood pressure (BP) was assessed at an interval of 2 weeks for 3 months. Fasting blood glucose (FBG) and lipid profile were estimated at baseline and then at 12 weeks. Results: Olmesartan and telmisartan were more efficacious than losartan in reducing diastolic BP (DBP). There was a statistically significant decrease in mean blood glucose level (P < 0.02) after 12 weeks of treatment in telmisartan group when compared to baseline. Serum total cholesterol, triglycerides, and low‑density lipoproteins decreased significantly after 12‑week treatment with olmesartan and telmisartan. Conclusions: The most efficacious drug in reducing BP is Olmesartan whereas telmisartan and losartan show equal efficacy. Telmisartan shows the most favorable effects on FBG and lipid profile.

    KEYWORDS

    Open in new tab

    REFERENCES

    As published

    Showing references and in-text citations exactly as published.

      Cite this article

      SELECT FORMAT

      Kalikar, M., Nivangune, K. S., Dakhale, G. N., Bajait, C. S., Sontakke, S. D., Motghare, V. M., & Budania, R. (2017). Efficacy and Tolerability of Olmesartan, Telmisartan, and Losartan in Patients of Stage I Hypertension: A Randomized, Open‑label Study. Journal of Pharmacology and Pharmacotherapeutics, 8(3), 106–111. https://doi.org/10.4103/jpp.JPP_39_17